Bio-path Holdings Inc (NASDAQ:BPTH) Could Burn Your Long Portfolio After More Shorts

May 18, 2018 - By John Moody

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Logo

Investors sentiment increased to 1.43 in Q4 2017. Its up 0.82, from 0.61 in 2017Q3. It improved, as 0 investors sold Bio-Path Holdings, Inc. shares while 7 reduced holdings. 4 funds opened positions while 6 raised stakes. 12.58 million shares or 18.70% more from 10.60 million shares in 2017Q3 were reported.
Deutsche Bancshares Ag reported 223 shares. Bbr Partners Ltd Com accumulated 15,178 shares or 0% of the stock. Ironwood Invest Counsel Ltd Liability Corporation invested 0% of its portfolio in Bio-Path Holdings, Inc. (NASDAQ:BPTH). National Bank Of Montreal Can owns 1,995 shares. Moreover, Wells Fargo And Mn has 0% invested in Bio-Path Holdings, Inc. (NASDAQ:BPTH) for 13,500 shares. Millennium Mngmt Limited Liability stated it has 0% in Bio-Path Holdings, Inc. (NASDAQ:BPTH). Geode Management Limited Liability Com holds 0% or 524,570 shares in its portfolio. California Public Employees Retirement holds 0% or 115,900 shares. Bancorp Of America De invested in 9,300 shares. Creative Planning accumulated 50,000 shares or 0% of the stock. Meeder Asset reported 6,592 shares. Raymond James Advsr Incorporated has 0% invested in Bio-Path Holdings, Inc. (NASDAQ:BPTH) for 149,276 shares. University Of Texas Managment Co owns 3.83M shares for 2.96% of their portfolio. State Street reported 46,400 shares stake. New York-based Bnp Paribas Arbitrage Sa has invested 0% in Bio-Path Holdings, Inc. (NASDAQ:BPTH).

The stock of Bio-path Holdings Inc (NASDAQ:BPTH) registered an increase of 5.88% in short interest. BPTH’s total short interest was 546,000 shares in May as published by FINRA. Its up 5.88% from 515,700 shares, reported previously. With 224,400 shares average volume, it will take short sellers 2 days to cover their BPTH’s short positions.

The stock increased 0.57% or $0.01 during the last trading session, reaching $1.75. About 500 shares traded. Bio-Path Holdings, Inc. (NASDAQ:BPTH) has declined 76.76% since May 18, 2017 and is downtrending. It has underperformed by 88.31% the S&P500.

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development firm in the United States. The company has market cap of $19.85 million. The firm develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid backbone modification intended to protect the DNA from destruction. It currently has negative earnings. The Company’s lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer.

More notable recent Bio-Path Holdings, Inc. (NASDAQ:BPTH) news were published by: Nasdaq.com which released: “Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board” on May 10, 2018, also Seekingalpha.com with their article: “Bio-Path Holdings’ (BPTH) CEO Peter Nielsen on Q1 2018 Results – Earnings Call Transcript” published on May 16, 2018, Globenewswire.com published: “Bio-Path Holdings Reports First Quarter 2018 Financial Results” on May 16, 2018. More interesting news about Bio-Path Holdings, Inc. (NASDAQ:BPTH) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” published on May 16, 2018 as well as Streetinsider.com‘s news article titled: “Pre-Open Movers 04/19 (BPTH) (GWW) (AMZN) Higher; (ACET) (HMNY) (SNBR) (PIR) Lower (more…)” with publication date: April 19, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.